Trial Profile
A One-Year, Open-Label Study With Teduglutide for Subjects With Parenteral Nutrition-dependent Short Bowel Syndrome Who Completed Study CL0600-021
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jun 2021
Price :
$35
*
At a glance
- Drugs Teduglutide (Primary)
- Indications Short bowel syndrome
- Focus Adverse reactions
- Acronyms STEPS 3
- Sponsors NPS Pharmaceuticals
- 18 May 2014 New trial record
- 16 Sep 2013